-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Maximizing Revenue from an Infusion Center

Program: Special-Interest Sessions
Session: Special Session on Sickle Cell Disease Centers
Saturday, December 9, 2023, 9:30 AM-11:00 AM

Sophie Lanzkron

Johns Hopkins Medical Institute, Baltimore, MD

Disclosures: Lanzkron: Imara: Research Funding; Novartis: Research Funding; Global Blood Therapeutics: Research Funding; Takeda: Research Funding; CSL-Behring: Research Funding; HRSA: Research Funding; PCORI: Research Funding; MD CHRC: Research Funding; Bluebird Bio: Consultancy; Novo Nordisk: Consultancy; Magenta: Consultancy; Pfizer: Current equity holder in publicly-traded company; Teva: Current equity holder in publicly-traded company.

See more of: Special Session on Sickle Cell Disease Centers
See more of: Special-Interest Sessions
Previous Presentation | Next Presentation >>